Antinol® Latest Studies
Sorted by recent
Filter Studies by Smart TagsBone & JointCardiovascularCatDogEAB 277™EfficacyExotic PetImmunologyNeuro & BehaviorOphthalmologyOralRabbitRenalRespiratoryRodentSafetySkinUTI
The Preliminary study of the Clinical outcome of using the PCSO-524 polyunsaturated fatty acid compound (Antinol) in the treatment of Canine Osteoarthritis and degenerative spinal diseases
The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University.
Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome.
All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks.
Updated Study Topics
New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted